127 related articles for article (PubMed ID: 15194539)
1. Cytokine production during myeloablative and reduced intensity therapy before allogeneic stem cell transplantation.
Remberger M; Sundberg B
Haematologica; 2004 Jun; 89(6):710-6. PubMed ID: 15194539
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation.
Seidel MG; Fritsch G; Matthes-Martin S; Lawitschka A; Lion T; Pötschger U; Rosenmayr A; Fischer G; Gadner H; Peters C
Haematologica; 2005 Oct; 90(10):1405-14. PubMed ID: 16219578
[TBL] [Abstract][Full Text] [Related]
4. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
5. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
[TBL] [Abstract][Full Text] [Related]
8. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
Tanosaki R; Uike N; Utsunomiya A; Saburi Y; Masuda M; Tomonaga M; Eto T; Hidaka M; Harada M; Choi I; Yamanaka T; Kannagi M; Matsuoka M; Okamura J
Biol Blood Marrow Transplant; 2008 Jun; 14(6):702-8. PubMed ID: 18489996
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
[TBL] [Abstract][Full Text] [Related]
11. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
12. [Reduced intensity of BuCy conditioning regimen for transplantation in the treatment of malignant hematologic diseases].
Chen H; Lu DP; Huang XJ; Liu KY; Xu LP; Han W; Ren HY; Chen YH; Liu DH; Lu J; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):273-6. PubMed ID: 15949287
[TBL] [Abstract][Full Text] [Related]
13. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
14. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation.
Ferrà C; de Sanjosé S; Gallardo D; Berlanga JJ; Rueda F; Marìn D; de la Banda E; Ancìn I; Peris J; Garcìa J; Grañena A
Haematologica; 1998 Dec; 83(12):1082-7. PubMed ID: 9949625
[TBL] [Abstract][Full Text] [Related]
15. Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation.
Weber M; Kröger N; Langer F; Hansen A; Zabelina T; Eifrig B; Hossfeld DK; Zander AR
Bone Marrow Transplant; 2003 May; 31(9):817-22. PubMed ID: 12732891
[TBL] [Abstract][Full Text] [Related]
16. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
Hartwig UF; Winkelmann N; Wehler T; Kreiter S; Schneider PM; Meyer RG; Ullmann AJ; Huber C; Kolbe K; Herr W
Ann Hematol; 2005 May; 84(5):331-8. PubMed ID: 15726363
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
[TBL] [Abstract][Full Text] [Related]
19. The kinetics of circulating cytokines including IL-6, TNF-alpha, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation.
Min CK; Lee WY; Min DJ; Lee DG; Kim YJ; Park YH; Kim HJ; Lee S; Kim DW; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2001 Nov; 28(10):935-40. PubMed ID: 11753547
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
